Skip to main content
Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc. — Investor Relations & Filings

Ticker · TRDA ISIN · US29384C1080 US Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2023-05-10 Interim / Quarterly Rep…
Country US United States of America
Listing US TRDA

About Entrada Therapeutics, Inc.

https://www.entradatx.com/

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of medicines to treat devastating diseases. The company's proprietary Endosomal Escape Vehicle (EEV) platform is designed to enable the intracellular delivery of a wide range of therapeutics, allowing access to targets that have historically been considered undruggable. Entrada's development pipeline is concentrated on rare conditions, with programs targeting neuromuscular diseases, including Duchenne muscular dystrophy, as well as ocular diseases. The company's mission is to transform the lives of patients by establishing EEV-based therapeutics as a new treatment modality.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2023
2023-05-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Entrada Therapeutics, Inc. It announces the company's financial results for the quarter ended March 31, 2023, and includes a press release as an exhibit. The text explicitly states that the press release is being furnished as Exhibit 99.1 and that the information is intended to be furnished and not filed, indicating this is an announcement of financial results rather than the full financial report itself. The document length is 3721 characters, which is relatively short and consistent with a brief announcement rather than a comprehensive report. According to the classification rules, initial announcements of quarterly financial results (key highlights only) correspond to an Earnings Release (ER). Therefore, this document should be classified as an Earnings Release (ER).
2023-05-10 English
FORM 4
Director's Dealing
2023-05-01 English
Regulatory Filings 2023
Regulatory Filings
2023-04-27 English
ARS
Annual Report
2023-04-25 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically labeled as "Definitive Additional Materials" related to the 2023 Annual Meeting of Stockholders for Entrada Therapeutics, Inc. It includes voting instructions, proposals such as election of directors and ratification of the independent auditor, and information on how to vote. The content is typical of proxy solicitation materials sent to shareholders to inform and request votes for the annual meeting. The document length is 3500 characters, which is relatively short and consistent with proxy materials rather than a full annual report or other detailed filings. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI).
2023-04-25 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.